Kohei Shitara/X
Jun 15, 2025, 08:16
Kohei Shitara: Pleased To Report FGFR2b Expression In Gastric Cancer and Relationship With Other Biomarkers Published in ESMO Open
Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared a post on X:
“Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers in ESMO Open.
The results of bemarituzumab phase 3 studies are awaited.”
Title: Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Journal: ESMO Open
Authors: S. Sato, S.L. Rhodes, Y. Aoki, I. Nakayama, T. Hashimoto, J. Hawkins, R.E. Yanes, C.-H. Chang, Y. Nakamura, A. Kawazoe, S. Mishima, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, S. Yoshino, S. Reading, H. Honeycutt, E. Finger, I. Endo, N. Sakamoto, T. Kuwata, T. Yoshino, K. Shitara
More posts featuring Kohei Shitara on OncoDaily.
A. Kawazoe
C.-H. Chang
cancer
D. Kotani
E. Finger
ESMO Open
FGFR2b
gastric cancer
H. Bando
H. Honeycutt
I. Endo
I. Nakayama
J. Hawkins
K. Shitara
Kohei shitara
N. Sakamoto
OncoDaily
Oncology
R.E. Yanes
S. Mishima
S. Reading
S. Sato
S. Yoshino
S.L. Rhodes
T. Hashimoto
T. Kojima
T. Kuwata
T. Yoshino
Y. Aoki
Y. Kuboki
Y. Nakamura
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38